New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:22 EDTBINDBIND Therapeutics barasertib data positive, says JMP Securities
JMP Securities notes that pre-clinical studies of BIND's barasertib showed enhanced anti-tumor activity and reduced bone marrow toxicity. The firm thinks the company could overcome the need for lengthy drug infusion and high rates of febrile neutropenia, shown in a previous studiy, by extending the half-life of the drug. The firm reiterates a $30 price target and Outperform rating on the stock.
News For BIND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:43 EDTBINDBIND Therapeutics data encouraging, says JMP Securities
JMP Securities believes that data for BIND's BIND-014 showed encouraging evidence of activity and overall survival in difficult-to-treat subsets of non-small cell lung cancer. The firm reiterates a $30 price target and Outperform rating on BIND.
November 19, 2014
07:03 EDTBINDBIND Therapeutics says BIND-014 met primary objective in Phase 2 study
Subscribe for More Information
November 18, 2014
07:20 EDTBINDEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use